Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2017
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy. This report provides information on the therapeutic development based on Chimeric Antigen Receptor (CAR) T cell Immunotherapy mechanism of action dealing with around 120+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight’s Report also assesses the Chimeric Antigen Receptor (CAR) T cell Immunotherapy therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 28+ active companies involved in the therapeutic development of the products.
SCOPE
DelveInsight’s, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy. This report provides information on the therapeutic development based on Chimeric Antigen Receptor (CAR) T cell Immunotherapy mechanism of action dealing with around 120+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight’s Report also assesses the Chimeric Antigen Receptor (CAR) T cell Immunotherapy therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 28+ active companies involved in the therapeutic development of the products.
SCOPE
- The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
- The report also gives the information of dormant pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Complete MOA intelligence and complete understanding over therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
1. REPORT INTRODUCTION
2. EXECUTIVE SUMMARY SNAPSHOT
3. EXECUTIVE SUMMARY
4. INTRODUCTION
4.1. Chimeric antigen receptor (CAR) T-cells
4.2. History
4.3. CARs and Generations
4.4. Advantages of CAR-T cells
4.5. Adverse Events with CAR T-cell Therapy
4.6. Limitations of Existing Technologies for CAR T-Cells
5. CAR-T CELL THERAPY-ANALYSIS
5.1. CAR-T Collaboration Deals
5.1.1. CAR-T Cells Therapy Collaborations and Deal Year
5.1.2. Collaborations & Deal Value Trends
5.1.3. Companies collaborations for future developments
5.2. CAR-T Acquisitions Deals
5.2.1. CAR-T Cells Therapy Acquisitions Trends
5.2.2. CAR-T Cells Therapy Acquisitions Offerings by Big Giants
5.3. New facilityfor the development of CAR-T cells
5.4. JCAR015: Major Set Back for Juno Therapeutics
5.5. CAR-T Licensing Opportunities
5.6. Pipeline Scenario
5.6.1. Pipeline Products under Development-An Overview
5.6.2. Pipeline Products under Development by Company
5.6.3. CAR T-cells Therapeutic Areas & Companies
5.6.4. CAR-T cells Targeted Antigens
5.7. Target: CD19, Related Drug Products, Phase & Company
5.7.1. CAR-T Therapies-Clinical trials & Completion Year
5.7.2. CAR T-cell Technologies & Companies Involved
5.7.3. CAR-T Safety Switches & Company involved
5.7.4. Companies with Upcoming CAR-T Therapeutics
6. PIPELINE PROFILES
6.1. Company A
6.1.1. Drug A: Company
Product Description
Research and Development
Clinical Studies
6.1.2. Drug B: Company
Product Description
Research and Development
Clinical Studies
6.2. Company B
6.2.1. Drug C: Company
Product Description
Research and Development
Clinical Studies
To be continued in report…
7. UPCOMING TECHNOLOGIES BETTER THAN CARS
8. MARKET DRIVERS
9. MARKET BARRIERS
10. SWOT ANALYSIS
11. REPORT METHODOLOGY
12. CONSULTING SERVICES
2. EXECUTIVE SUMMARY SNAPSHOT
3. EXECUTIVE SUMMARY
4. INTRODUCTION
4.1. Chimeric antigen receptor (CAR) T-cells
4.2. History
4.3. CARs and Generations
4.4. Advantages of CAR-T cells
4.5. Adverse Events with CAR T-cell Therapy
4.6. Limitations of Existing Technologies for CAR T-Cells
5. CAR-T CELL THERAPY-ANALYSIS
5.1. CAR-T Collaboration Deals
5.1.1. CAR-T Cells Therapy Collaborations and Deal Year
5.1.2. Collaborations & Deal Value Trends
5.1.3. Companies collaborations for future developments
5.2. CAR-T Acquisitions Deals
5.2.1. CAR-T Cells Therapy Acquisitions Trends
5.2.2. CAR-T Cells Therapy Acquisitions Offerings by Big Giants
5.3. New facilityfor the development of CAR-T cells
5.4. JCAR015: Major Set Back for Juno Therapeutics
5.5. CAR-T Licensing Opportunities
5.6. Pipeline Scenario
5.6.1. Pipeline Products under Development-An Overview
5.6.2. Pipeline Products under Development by Company
5.6.3. CAR T-cells Therapeutic Areas & Companies
5.6.4. CAR-T cells Targeted Antigens
5.7. Target: CD19, Related Drug Products, Phase & Company
5.7.1. CAR-T Therapies-Clinical trials & Completion Year
5.7.2. CAR T-cell Technologies & Companies Involved
5.7.3. CAR-T Safety Switches & Company involved
5.7.4. Companies with Upcoming CAR-T Therapeutics
6. PIPELINE PROFILES
6.1. Company A
6.1.1. Drug A: Company
Product Description
Research and Development
Clinical Studies
6.1.2. Drug B: Company
Product Description
Research and Development
Clinical Studies
6.2. Company B
6.2.1. Drug C: Company
Product Description
Research and Development
Clinical Studies
To be continued in report…
7. UPCOMING TECHNOLOGIES BETTER THAN CARS
8. MARKET DRIVERS
9. MARKET BARRIERS
10. SWOT ANALYSIS
11. REPORT METHODOLOGY
12. CONSULTING SERVICES
LIST OF TABLES
Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy – Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017
Table 1: CARs Generations-Associated Target Antigens and Indications
Table 2: CAR-T Cells Therapy – Company Collaborations and Deal Year, 2017
Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2017
Table 4: CAR-T Cells Therapy collaboration Deals and Values, 2017
Table 5: Companies CAR-T Investment for future developments, 2017
Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2017
Table 7:Companies open for licensing and collaborations, 2017
Table 8:Number of Products under Development, 2017
Table 9:Number of Products under Development by Companies, 2017
Table 10:Number of Products under Development by Indication, 2017
Table 11:Number of Products Targeting CD19 Antigen, 2017
Table 12:Number of Products Targeting Other Antigens, 2017
Table 13: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2017
Table 14:CAR T-cell Companies and Technologies, 2017
LIST OF FIGURES
Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017
Figure 1: Companies Collaborations vs. Financial year, 2017
Figure 2: Number of Companies Collaborations, 2017
Figure 3: Collaborations and Upfront Deal Values (In million, $), 2017
Figure 4: Number of Products under Development, 2017
Figure 5: Number of Products under Development by Companies, 2017
Figure 6: Number of Products under Development by Indication, 2017
Figure 7: CAR-T cell Targeted Antigens (%), 2017
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2017
Figure 9: Number of CAR-T Clinical Trials & Completion Year, 2017
Figure 10:CAR T-cell Companies and Technologies, 2017
